- Home
- INSM vs NMR Comparison
INSM vs NMR Comparison
Compare INSM & NMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- NMR
- Stock Information
- Founded
- INSM 1988
- NMR 1925
- Country
- INSM United States
- NMR Japan
- Employees
- INSM N/A
- NMR N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- NMR Investment Bankers/Brokers/Service
- Sector
- INSM Health Care
- NMR Finance
- Exchange
- INSM Nasdaq
- NMR Nasdaq
- Market Cap
- INSM 14.3B
- NMR N/A
- IPO Year
- INSM 2000
- NMR 1961
- Fundamental
- Price
- INSM $76.29
- NMR $6.15
- Analyst Decision
- INSM Strong Buy
- NMR Hold
- Analyst Count
- INSM 16
- NMR 1
- Target Price
- INSM $95.36
- NMR N/A
- AVG Volume (30 Days)
- INSM 1.5M
- NMR 522.6K
- Earning Date
- INSM 05-08-2025
- NMR 04-25-2025
- Dividend Yield
- INSM N/A
- NMR 3.42%
- EPS Growth
- INSM N/A
- NMR 184.58
- EPS
- INSM N/A
- NMR 0.67
- Revenue
- INSM $363,707,000.00
- NMR $11,988,627,534.00
- Revenue This Year
- INSM $30.31
- NMR $47.37
- Revenue Next Year
- INSM $118.39
- NMR N/A
- P/E Ratio
- INSM N/A
- NMR $8.64
- Revenue Growth
- INSM 19.17
- NMR 30.73
- 52 Week Low
- INSM $21.92
- NMR $4.66
- 52 Week High
- INSM $84.91
- NMR $6.99
- Technical
- Relative Strength Index (RSI)
- INSM 46.23
- NMR 45.76
- Support Level
- INSM $76.05
- NMR $6.53
- Resistance Level
- INSM $79.12
- NMR $6.67
- Average True Range (ATR)
- INSM 2.52
- NMR 0.10
- MACD
- INSM -0.02
- NMR 0.00
- Stochastic Oscillator
- INSM 38.63
- NMR 50.85
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.